“Real-World” Hospitalization Data on Patients Receiving CAR-T Cell Therapy
An investigation of a large performance improvement clinical database revealed that most individuals receiving CAR-T have diagnoses of ALL or large B-cell lymphoma.
An investigation of a large performance improvement clinical database revealed that most individuals receiving CAR-T have diagnoses of ALL or large B-cell lymphoma.
Researchers examined low-level estimates of ambient benzene to investigate whether it was associated with increased cancer incidence across a nationwide cohort.
According to results of an exploratory study, patients with Richter transformation may benefit from treatment with ibrutinib plus nivolumab.
Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.
Being able to identify which patients would respond to standard therapies allows for early adjustment in treatment and improves outcomes.
Findings from a previous study suggested that Q fever may significantly increase a person’s risk of nHL.
Previous findings showed that patients obinutuzumab plus bendamustine prolonged progression-free survival, but data was immature at the time of analysis.
Dual expression of MYC and BCL2 was associated with worse survival among patients with GCB-like DLBCL, though this status was not associated with any outcomes among patients with ABC-like DLBCL.
Data support use of bendamustine for patients treated with several lines of therapy, but whether this drug should be used in the first line is open to question.
More studies are needed to determine the association between periodontal disease and non-Hodgkin lymphoma.